XML 34 R57.htm IDEA: XBRL DOCUMENT v2.4.1.9
ALLIANCES (Gilead) (Details) (USD $)
In Millions, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Alliances Statement [Line Items]      
Alliance and other revenues $ 4,219us-gaap_OtherSalesRevenueNet $ 4,081us-gaap_OtherSalesRevenueNet $ 3,967us-gaap_OtherSalesRevenueNet
Equity in net loss of affiliates (107)us-gaap_IncomeLossFromEquityMethodInvestments (166)us-gaap_IncomeLossFromEquityMethodInvestments (183)us-gaap_IncomeLossFromEquityMethodInvestments
Deferred income 1,937us-gaap_DeferredRevenueAndCredits 1,525us-gaap_DeferredRevenueAndCredits  
Gilead [Member] | Bulk efavirenz component of Atripla [Member]      
Alliances Statement [Line Items]      
Total numbers of months to receive royalty payment from alliance partner 36 months    
Percentage of net sales recognized first year following the termination 55.00%bmy_PercentageOfNetSalesRecognizedFirstYearFollowingTheTermination
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
   
Percentage of net sales recognized second year following the termination 35.00%bmy_PercentageofNetSalesRecognizedSecondYearAfterTheTermination
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
   
Percentage of net sales recognized third year following the termination of the agreement 15.00%bmy_PercentageOfNetSalesRecognizedThirdYearFollowingTheTermination
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
   
Alliance and other revenues 1,255us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
1,366us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
1,267us-gaap_OtherSalesRevenueNet
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
Equity in net loss of affiliates 39us-gaap_IncomeLossFromEquityMethodInvestments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
17us-gaap_IncomeLossFromEquityMethodInvestments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
18us-gaap_IncomeLossFromEquityMethodInvestments
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
Deferred income $ 316us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember
$ 468us-gaap_DeferredRevenueAndCredits
/ bmy_AlliancesAndCollaborationCompaniesAxis
= bmy_GileadMember
/ us-gaap_ProductOrServiceAxis
= bmy_BulkEfavirenzComponentOfAtriplaMember